bounce predicted, page-9

Newtothegame, I'm not looking to convince you or anyone else about Avexa's merits or otherwise. After all, I never imagined it would fall below 70c - what would I know! I'm simply pointing out that Tharlow has a history of downramping on this and at least 10 other stocks and has been exposed as such on multiple threads.

My reasons for staying with Avexa are pretty simple - $80 million in cash, good phase IIb results, no HIV drug entering phase 3 has failed to get to market, various other things in their research pipeline, price has trickled to far below what most brokers covering the stock regard as fair value, reasons for fall seem more to do with poor management of share issue than any fundamental issue..etc etc.